Muscle Protein Degradation in Cancer Cachexia
Author Information
Author(s): K.L. Smith, M.J. Tisdale
Primary Institution: Cancer Research Campaign Experimental Chemotherapy Group, Pharmaceutical Sciences Institute, Aston University
Hypothesis
The study investigates the mechanism of protein degradation in skeletal muscle during cancer cachexia.
Conclusion
The study found that muscle protein degradation in cancer cachexia is associated with increased levels of prostaglandin E2 (PGE2).
Supporting Evidence
- The study showed that serum from cachectic mice increased protein degradation in isolated muscle.
- Prostaglandin E2 levels were significantly elevated in muscle after incubation with serum from cachectic mice.
- Indomethacin and eicosapentaenoic acid inhibited muscle protein degradation.
Takeaway
When mice with cancer lose weight, their muscles break down protein faster, and this is linked to a chemical called PGE2.
Methodology
The study used NMRI mice bearing the MAC16 tumor to measure protein degradation in isolated gastrocnemius muscle by assessing tyrosine release.
Limitations
The study primarily used a single animal model and may not fully represent human cancer cachexia.
Participant Demographics
Pure strain female NMRI mice were used in the study.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website